ACRX Share Price

Open 2.65 Change Price %
High 2.65 1 Day -0.05 -1.89
Low 2.50 1 Week 0.10 4.00
Close 2.60 1 Month 0.05 1.96
Volume 410695 1 Year -0.71 -21.45
52 Week High 4.08
52 Week Low 2.25
ACRX Important Levels
Resistance 2 2.74
Resistance 1 2.68
Pivot 2.58
Support 1 2.52
Support 2 2.46
NASDAQ USA Most Active Stocks
GOOG 941.86 0.84%
GOOG 941.86 0.84%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DCTH 0.03 0.00%
ASTI 0.00 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
MNGA 1.92 966.67%
HAUP 0.17 88.89%
NUTR 42.15 50.54%
LOCM 0.09 50.00%
OPXAW 0.03 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
COOL 16.78 24.85%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

ACRX Technical Analysis 4
As on 22nd May 2017 ACRX Share Price closed @ 2.60 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.03 & Sell for SHORT-TERM with Stoploss of 2.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACRX Target for May
1st Target up-side 2.98
2nd Target up-side 3.25
3rd Target up-side 3.52
1st Target down-side 2.22
2nd Target down-side 1.95
3rd Target down-side 1.68
ACRX Other Details
Segment EQ
Market Capital 65612500.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.acelrx.com
ACRX Address
ACRX
351 Galveston Drive
Redwood City, CA 94063
United States
Phone: 650-216-3500
Fax: 650-216-6500
ACRX Latest News
Interactive Technical Analysis Chart AcelRx Pharmaceuticals, Inc. ( ACRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AcelRx Pharmaceuticals, Inc.
ACRX Business Profile
AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company has completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02, for the treatment of cancer breakthrough pain (BTP), and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. The Company is preparing to initiate two Phase 3 clinical trials for its product candidate, the Sufentanil NanoTab PCA System, or ARX-01. Its operations are based in Redwood City, California.